It's glucagon component might explain its superior benefits for liver health, as glucagon reduces fat synthesis and increases fat oxidation in the liver
10.1016/j.ejmech.2018.01.011 113 YamadaN.KarasawaT.KimuraH.WatanabeS.KomadaT.KamataR.et al (2020)
doi:10.2337/dbi19-0023 159
Last updated April 23, 2026
For this product-page article, RUO means the language stays focused on laboratory research, documentation review, and analytical verification
As an oral, once-daily therapy, TLC-2716 achieved triglyceride reductions of up to 62% in our highest-risk patients competitive with injectable agents in development alongside ~50% reductions in remnant cholesterol, broad improvements in atherogenic lipids, and meaningful reductions in liver fat